Characteristics of indications, clinical trial evidence, clinical benefits and the costs of price-negotiated multi-indication drugs for solid tumours in China
While we found that the NDPN policy has significantly reduced drug costs, we did not observe a significant correlation between costs and specific characteristics. This highlights a need for a more transparent pricing mechanism linked to clinical efficacy to improve the accessibility and affordability of cancer therapies that effectively balance the interests of pharmaceutical companies, patients, and health insurance funds.
Authors
- Pei Zhang (ORCID: https://orcid.org/0009-0003-4394-970X)
- Mengdie Zhang (ORCID: https://orcid.org/0009-0003-5176-2013)
- Jingxuan Wei (ORCID: https://orcid.org/0000-0003-0295-3764)
- Rui Ma (ORCID: https://orcid.org/0000-0002-7439-8344)
- Xiaodan Qian
- Yuwen Bao
- Xin Li (ORCID: https://orcid.org/0000-0003-3951-8061)
- Dan Su (ORCID: https://orcid.org/0000-0002-1146-8368)
- Lingli Zhang (ORCID: https://orcid.org/0009-0002-2386-3055)
Institutions
- China Pharmaceutical University (CN)
- Nanjing Traditional Chinese Medicine Hospital (CN)
- Changzhou No.2 People's Hospital (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Global Health
- Published
- 2025-05-08
- DOI
- https://doi.org/10.7189/jogh.15.04121
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00